Ajooni Historical Balance Sheet

AJOONI Stock

7.83 0.04 0.51%

Trend analysis of Ajooni Biotech Limited balance sheet accounts such as Total Current Liabilities of 58.3 M, Total Stockholder Equity of 448.4 M or Net Debt of 25.9 M provides information on Ajooni Biotech's total assets, liabilities, and equity, which is the actual value of Ajooni Biotech to its prevalent stockholders. By breaking down trends over time using Ajooni Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Ajooni Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ajooni Biotech is a good buy for the upcoming year.

Ajooni Biotech Inventory

189.59 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ajooni Biotech Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Ajooni Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Ajooni Biotech at a specified time, usually calculated after every quarter, six months, or one year. Ajooni Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ajooni Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ajooni currently owns. An asset can also be divided into two categories, current and non-current.

Ajooni Biotech Balance Sheet Chart

At present, Ajooni Biotech's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 58.3 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 47.5 M.

Total Assets Total Current Liabilities Total Stockholder Equity Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Ajooni Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ajooni Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Ajooni Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ajooni Biotech Limited are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Accounts Payable

An accounting item on the balance sheet that represents Ajooni Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Ajooni Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Ajooni Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ajooni Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ajooni Biotech Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	100.6M	152.1M	30.1M	58.3M
Total Assets	290.2M	587.3M	475.2M	499.0M

Total Current Liabilities Total Assets

Ajooni Biotech balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Inventory	Other Current Assets	Non Current Liabilities Total	Short Long Term Debt Total	Short Term Debt	Other Assets	Long Term Debt	Short Term Investments
Total Assets		0.73	0.97	0.57	0.9	0.74	0.11	0.13	0.19	0.92	0.74	0.99	0.98	0.2	0.9	0.9	0.02	0.45	0.83	0.88	0.51	0.53	0.31	-0.01	0.76	0.57
Total Current Liabilities	0.73		0.55	0.84	0.51	0.92	0.11	0.13	-0.14	0.51	0.98	0.71	0.63	0.52	0.48	0.77	0.02	0.8	0.33	0.54	0.54	0.89	0.77	-0.07	0.68	0.86
Total Stockholder Equity	0.97	0.55		0.41	0.92	0.59	0.08	0.1	0.26	0.96	0.56	0.97	0.98	0.04	0.94	0.83	-0.01	0.28	0.9	0.89	0.39	0.34	0.1	-0.05	0.7	0.41
Net Debt	0.57	0.84	0.41		0.51	0.75	-0.28	-0.27	0.16	0.31	0.82	0.6	0.5	0.33	0.45	0.5	-0.19	0.72	0.33	0.36	0.44	0.85	0.7	-0.33	0.75	0.74
Retained Earnings	0.9	0.51	0.92	0.51		0.55	-0.04	-0.03	0.42	0.8	0.55	0.94	0.94	-0.1	0.9	0.7	-0.19	0.35	0.86	0.8	0.51	0.37	0.12	0.06	0.76	0.43
Accounts Payable	0.74	0.92	0.59	0.75	0.55		-0.1	-0.07	-0.19	0.57	0.87	0.72	0.66	0.32	0.53	0.76	-0.27	0.84	0.33	0.57	0.37	0.7	0.52	-0.14	0.76	0.91
Cash	0.11	0.11	0.08	-0.28	-0.04	-0.1		1.0	-0.06	0.08	0.16	0.07	0.1	0.15	-0.03	0.18	0.6	-0.07	0.0	0.03	0.29	0.23	0.36	0.62	-0.18	-0.02
Cash And Short Term Investments	0.13	0.13	0.1	-0.27	-0.03	-0.07	1.0		-0.08	0.1	0.18	0.09	0.12	0.17	-0.02	0.2	0.6	-0.05	0.01	0.06	0.3	0.24	0.37	0.61	-0.17	0.0
Common Stock Shares Outstanding	0.19	-0.14	0.26	0.16	0.42	-0.19	-0.06	-0.08		0.19	-0.09	0.29	0.31	-0.45	0.48	-0.03	-0.22	-0.24	0.52	-0.03	0.13	0.09	-0.07	-0.09	0.46	-0.16
Other Stockholder Equity	0.92	0.51	0.96	0.31	0.8	0.57	0.08	0.1	0.19		0.49	0.9	0.92	0.1	0.92	0.81	0.01	0.16	0.88	0.85	0.28	0.24	0.01	-0.15	0.64	0.32
Total Liab	0.74	0.98	0.56	0.82	0.55	0.87	0.16	0.18	-0.09	0.49		0.71	0.63	0.56	0.5	0.78	0.08	0.75	0.38	0.52	0.71	0.88	0.78	0.09	0.64	0.8
Total Current Assets	0.99	0.71	0.97	0.6	0.94	0.72	0.07	0.09	0.29	0.9	0.71		0.99	0.09	0.93	0.85	-0.07	0.45	0.85	0.84	0.49	0.54	0.29	-0.04	0.82	0.57
Common Stock	0.98	0.63	0.98	0.5	0.94	0.66	0.1	0.12	0.31	0.92	0.63	0.99		0.01	0.94	0.83	-0.07	0.39	0.87	0.85	0.44	0.45	0.21	-0.01	0.79	0.52
Other Current Liab	0.2	0.52	0.04	0.33	-0.1	0.32	0.15	0.17	-0.45	0.1	0.56	0.09	0.01		-0.06	0.45	0.59	0.2	-0.02	0.22	0.47	0.42	0.54	0.02	-0.11	0.16
Property Plant And Equipment Net	0.9	0.48	0.94	0.45	0.9	0.53	-0.03	-0.02	0.48	0.92	0.5	0.93	0.94	-0.06		0.68	-0.15	0.14	0.96	0.71	0.39	0.32	0.04	-0.14	0.77	0.32
Non Current Assets Total	0.9	0.77	0.83	0.5	0.7	0.76	0.18	0.2	-0.03	0.81	0.78	0.85	0.83	0.45	0.68		0.19	0.53	0.61	0.85	0.52	0.55	0.41	0.07	0.61	0.62
Non Currrent Assets Other	0.02	0.02	-0.01	-0.19	-0.19	-0.27	0.6	0.6	-0.22	0.01	0.08	-0.07	-0.07	0.59	-0.15	0.19		-0.28	0.01	0.13	0.24	0.11	0.33	0.26	-0.47	-0.26
Net Receivables	0.45	0.8	0.28	0.72	0.35	0.84	-0.07	-0.05	-0.24	0.16	0.75	0.45	0.39	0.2	0.14	0.53	-0.28		-0.06	0.37	0.28	0.74	0.65	0.0	0.6	0.95
Inventory	0.83	0.33	0.9	0.33	0.86	0.33	0.0	0.01	0.52	0.88	0.38	0.85	0.87	-0.02	0.96	0.61	0.01	-0.06		0.68	0.44	0.19	-0.05	-0.07	0.6	0.1
Other Current Assets	0.88	0.54	0.89	0.36	0.8	0.57	0.03	0.06	-0.03	0.85	0.52	0.84	0.85	0.22	0.71	0.85	0.13	0.37	0.68		0.3	0.29	0.13	-0.06	0.51	0.4
Non Current Liabilities Total	0.51	0.54	0.39	0.44	0.51	0.37	0.29	0.3	0.13	0.28	0.71	0.49	0.44	0.47	0.39	0.52	0.24	0.28	0.44	0.3		0.52	0.49	0.57	0.27	0.29
Short Long Term Debt Total	0.53	0.89	0.34	0.85	0.37	0.7	0.23	0.24	0.09	0.24	0.88	0.54	0.45	0.42	0.32	0.55	0.11	0.74	0.19	0.29	0.52		0.94	-0.05	0.63	0.76
Short Term Debt	0.31	0.77	0.1	0.7	0.12	0.52	0.36	0.37	-0.07	0.01	0.78	0.29	0.21	0.54	0.04	0.41	0.33	0.65	-0.05	0.13	0.49	0.94		0.07	0.34	0.64
Other Assets	-0.01	-0.07	-0.05	-0.33	0.06	-0.14	0.62	0.61	-0.09	-0.15	0.09	-0.04	-0.01	0.02	-0.14	0.07	0.26	0.0	-0.07	-0.06	0.57	-0.05	0.07		-0.29	-0.03
Long Term Debt	0.76	0.68	0.7	0.75	0.76	0.76	-0.18	-0.17	0.46	0.64	0.64	0.82	0.79	-0.11	0.77	0.61	-0.47	0.6	0.6	0.51	0.27	0.63	0.34	-0.29		0.7
Short Term Investments	0.57	0.86	0.41	0.74	0.43	0.91	-0.02	0.0	-0.16	0.32	0.8	0.57	0.52	0.16	0.32	0.62	-0.26	0.95	0.1	0.4	0.29	0.76	0.64	-0.03	0.7

Click cells to compare fundamentals

Ajooni Biotech Account Relationship Matchups

Ajooni Biotech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	230.7M	280.3M	290.2M	587.3M	475.2M	499.0M
Total Current Liabilities	58.5M	104.8M	100.6M	152.1M	30.1M	58.3M
Total Stockholder Equity	158.9M	156.5M	163.8M	416.7M	427.1M	448.4M
Net Debt	49.0M	65.4M	52.9M	48.7M	17.4M	25.9M
Retained Earnings	63.6M	44.5M	55M	66.2M	86.9M	91.3M
Accounts Payable	19.3M	54.0M	68.0M	101.1M	15.8M	29.2M
Cash	1.2M	2.4M	573.9K	3.1M	4.3M	7.0M
Cash And Short Term Investments	1.2M	2.4M	573.9K	4.9M	4.3M	7.1M
Common Stock Shares Outstanding	38.6M	53.0M	56.7M	5.8M	86.4M	47.5M
Liabilities And Stockholders Equity	230.7M	280.3M	290.2M	587.3M	475.2M	499.0M
Other Stockholder Equity	11.3M	30.1M	63.8M	178.0M	178.0M	186.9M
Total Liab	71.8M	123.8M	126.4M	170.6M	48.1M	76.7M
Total Current Assets	175.1M	214.3M	219.3M	346.7M	323.3M	339.4M
Common Stock	61.6M	84.1M	100.1M	175.2M	175.2M	184.0M
Other Current Liab	499.6K	381.4K	333.1K	11.2M	570K	541.5K
Property Plant And Equipment Net	20.7M	51.6M	62.1M	65.5M	112.4M	118.1M
Non Current Assets Total	55.6M	66.0M	70.9M	240.6M	151.9M	80.7M
Non Currrent Assets Other	2.8M	1.4M	(69.1M)	15M	15.0M	8.0M
Net Receivables	129.1M	138.7M	139.4M	205.5M	(26.9M)	(25.5M)
Inventory	32.9M	53.8M	58.8M	69.9M	180.6M	189.6M
Other Current Assets	141.0M	11.5M	12.7M	268.6M	165.3M	173.6M
Non Current Liabilities Total	13.3M	19.0M	25.8M	18.5M	18.0M	22.0M
Short Long Term Debt Total	50.3M	67.8M	53.5M	51.8M	21.7M	20.6M
Short Term Debt	36.9M	48.9M	27.7M	34.3M	4.9M	4.6M
Long Term Debt	13.3M	19.0M	25.8M	17.5M	20.1M	12.4M
Short Term Investments	661K	1.6M	1.2M	1.8M	22K	20.9K
Long Term Debt Total	13.3M	19.0M	25.8M	17.5M	20.1M	13.5M
Property Plant Equipment	20.7M	51.6M	62.1M	65.5M	75.3M	79.1M
Net Tangible Assets	158.9M	156.5M	163.8M	416.7M	479.2M	503.2M
Current Deferred Revenue	1.9M	1.5M	4.5M	5.7M	83K	78.9K
Net Invested Capital	209.2M	224.3M	217.3M	468.5M	538.7M	274.7M
Short Long Term Debt	36.9M	48.9M	27.7M	34.3M	39.4M	33.9M
Non Current Liabilities Other	(0.13)	0.32	0.11	(1.0)	(0.9)	(0.85)
Net Working Capital	116.6M	109.5M	118.7M	194.6M	223.8M	140.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in Ajooni Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ajooni Historical Balance Sheet

Ajooni Biotech Inventory

189.59 Million

About Ajooni Balance Sheet Analysis

Ajooni Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Accounts Payable

Ajooni Biotech balance sheet Correlations

Ajooni Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ajooni Biotech balance sheet Accounts

Also Currently Popular

Other Information on Investing in Ajooni Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Total Current Assets
Common Stock	+ 0.98	Total Assets
Total Liab	+ 0.98	Total Current Liabilities
Common Stock	+ 0.98	Total Stockholder Equity

Long Term Debt	- 0.47	Non Currrent Assets Other
Other Current Liab	- 0.45	Common Stock Shares Outstanding
Other Assets	- 0.33	Net Debt
Long Term Debt	- 0.29	Other Assets
Net Receivables	- 0.28	Non Currrent Assets Other
Cash	- 0.28	Net Debt